What was Gongwin Biopharm Holdings Co., Ltd.’s price range in the past 12 months?
Gongwin Biopharm Holdings Co., Ltd. lowest stock price was TWD 58.30 and its highest was TWD 149.00 in the past 12 months.
What is Gongwin Biopharm Holdings Co., Ltd.’s market cap?
Gongwin Biopharm Holdings Co., Ltd.’s market cap is TWD 12.81B.
When is Gongwin Biopharm Holdings Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Gongwin Biopharm Holdings Co., Ltd.’s earnings last quarter?
Gongwin Biopharm Holdings Co., Ltd. released its earnings results on May 14, 2026. The company reported -TWD 0.324 earnings per share for the quarter.
Is Gongwin Biopharm Holdings Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Gongwin Biopharm Holdings Co., Ltd. pay dividends?
Gongwin Biopharm Holdings Co., Ltd. does not currently pay dividends.
What is Gongwin Biopharm Holdings Co., Ltd.’s EPS estimate?
Gongwin Biopharm Holdings Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gongwin Biopharm Holdings Co., Ltd. have?
Gongwin Biopharm Holdings Co., Ltd. has 127,506,100 shares outstanding.
What happened to Gongwin Biopharm Holdings Co., Ltd.’s price movement after its last earnings report?
Gongwin Biopharm Holdings Co., Ltd. reported an EPS of -TWD 0.324 in its last earnings report. Following the earnings report the stock price went down -5.03%.
Which hedge fund is a major shareholder of Gongwin Biopharm Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in TW:6617
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gongwin Biopharm Holdings Co., Ltd.
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concluded Phase III clinical trials for lung cancer. Additionally, PTS100 is currently progressing through Phase II clinical trials for liver cancer, while PTS-02 is being developed to address adenoid cystic carcinoma, and PTS500 targets malignant pleural effusion. Established in 2014, Gongwin Biopharm is headquartered in Taipei, Taiwan.